Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1484831 | 1.00 | MEN1 (0.32) | MEN1KMT2ATDP1KDM4EALDH1A1 | |
| SCHEMBL12752182 | 0.91 | KMT2A (0.36) | MEN1KMT2ATDP1 | |
| SCHEMBL1484440 | 0.90 | MEN1 (0.32) | MEN1KMT2ATDP1KDM4EALDH1A1 | |
| SCHEMBL1484441 | 0.90 | MEN1 (0.32) | MEN1KMT2ATDP1KDM4EALDH1A1 | |
| SCHEMBL1484462 | 0.89 | KMT2A (0.33) | MEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL1484461 | 0.89 | KMT2A (0.33) | MEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL12752359 | 0.86 | MEN1 (0.32) | MEN1KMT2ATDP1KDM4EALDH1A1 | |
| SCHEMBL12752363 | 0.86 | KMT2A (0.34) | MEN1KMT2ATDP1KDM4EALDH1A1 | |
| SCHEMBL642371 | 0.85 | KDM4E (0.36) | MEN1KMT2ATDP1KDM4EALDH1A1 | |
| SCHEMBL12752414 | 0.84 | KMT2A (0.35) | MEN1KMT2ATDP1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130078256-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-03-28 | — | — | US | disclosed |
| US-20130078256-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-03-28 | — | — | US | disclosed |
| US-20130078256-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-03-28 | — | — | US | disclosed |
| US-8334295-B2 | Pyrimidine derivatives as HIV reverse transcriptase inhibitors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-12-18 | — | — | US | disclosed |
| US-8334295-B2 | Pyrimidine derivatives as HIV reverse transcriptase inhibitors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-12-18 | — | — | US | disclosed |
| US-8334295-B2 | Pyrimidine derivatives as HIV reverse transcriptase inhibitors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-12-18 | — | — | US | disclosed |
| US-20110076276-A1 | Novel HIV reverse transcriptase inhibitors | GILEAD SCIENCES, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110076276-A1 | Novel HIV reverse transcriptase inhibitors | GILEAD SCIENCES, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110076276-A1 | Novel HIV reverse transcriptase inhibitors | GILEAD SCIENCES, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| WO-2009005674-A2 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110076276-A1 | Novel HIV reverse transcriptase inhibitors | POLR2E, POLR1E, POLR2H | MEN1 4798/4885KMT2A 1544/4885TDP1 160/4885 |
| US-20130078256-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | POLR2E, POLR1E, POLR2H | MEN1 4798/4885KMT2A 1544/4885TDP1 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.